New Market Research Report: Hair Loss Treatment Manufacturing in the US

[superman1]

Thick and thin: Rising sentiment will spur demand for treatments, but a patent cliff threatens profit.
Revenue for hair loss treatment manufacturers is expected to grow steadily over the next five years, supported by a patent cliff for major products Rogaine and Propecia. While the companies that manufacture these products will likely face a decline in profit, consumers will purchase more generic hair loss treatments. Furthermore, the aging population will increase the instances of male pattern baldness, boosting demand.
This industry develops and produces solutions that prevent or restore hair loss. Products in this industry include topical applications, orally ingestible treatments, hair transplants and laser follicle stimulation.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities
and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.

 

[abcdefg]

Maybe they should mention how none of that works and propecia is the only real treatment we have right now. So yeah I would say we are overdue for something new but given how bad our treatments are now almost anything is an improvement.
It is true though that propecia will start selling better soon when the price comes down a lot more when more generics enter the market so that is good at least.

 

[Synthetique]

Maybe they should mention how none of that works and propecia is the only real treatment we have right now. So yeah I would say we are overdue for something new but given how bad our treatments are now almost anything is an improvement.
It is true though that propecia will start selling better soon when the price comes down a lot more when more generics enter the market so that is good at least.

I think it's expected and unsurprising that we're "overdue" for an improvement; it's in a producer's interest to sit on a product for the duration of the patent and begin improvements only after its expiration. It's not a perfect system, but allocating profits ensures steady, though slow, progress.

The increased sales of finasteride/Propecia after the patent's expiration will demonstrate the true demand of this market and researchers and developers will respond with increased vigor in conducting their research.

The following entities appear particularly promising:
http://www.aderansresearch.com/
http://www.follicabio.com/
http://histogen.com/index.htm
http://www.replicel.com/